PhotoCure ASAFRA:PHS -1.32%73 Days Payable is 202.97 as of Mar. 2026, which is 28% below its 10-year median of 283.12. GuruFocus rates FRA:PHS with a GF Score™ of 73/100 and a GF Value™ of €6.33 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 923 Drug Manufacturers companies, PhotoCure ASA ranks better than 83.75% on this metric.
The historical rank and industry rank for PhotoCure ASA's Days Payable or its related term are showing as below:
FRA:PHS'
s Days Payable Range Over the Past 10 Years
Min: 124.06 Med: 283.12 Max: 379.71
Current: 193.2
During the past 13 years, PhotoCure ASA's highest Days Payable was 379.71. The lowest was 124.06. And the median was 283.12.
FRA:PHS's Days Payable is ranked better than 83.75% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs FRA:PHS: 193.20
PhotoCure ASA's Days Payable
declined
from Mar. 2025 (230.08) to Mar. 2026 (202.97).
It may suggest that PhotoCure ASAaccelerated paying its suppliers.
PhotoCure ASA Days Payable Related Terms
PhotoCure ASA Days Payable Historical Data
* Premium members only.
The historical data trend for PhotoCure ASA's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PHS vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's Days Payable distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
PhotoCure ASA's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhotoCure ASA (FRA:PHS) has a Days Payable of 202.97 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PhotoCure ASA and its competitors. This is 28% below median its historical median of 283.12. Over the past decade, PhotoCure ASA's Days Payable has ranged from 124.06 to 379.71. According to the industry distribution chart, PhotoCure ASA ranks #150 out of 923 companies in the Drug Manufacturers industry, placing it in the top 16.3%.
Is PhotoCure ASA's Days Payable too high?
PhotoCure ASA's current Days Payable of 202.97 is 28% below median its 10-year median of 283.12. Over the past 10 years, this metric has ranged from a low of 124.06 to a high of 379.71. The Drug Manufacturers industry median Days Payable is 90.98. PhotoCure ASA's value of 202.97 is 123.1% above this industry median. Based on the distribution chart, PhotoCure ASA ranks #150 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PhotoCure ASA has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #150 out of 923 companies for Days Payable. This places PhotoCure ASA in the top 16% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. PhotoCure ASA's value of 202.97 is 123.1% above this benchmark. Historically, PhotoCure ASA's own Days Payable has ranged from 124.06 to 379.71 over the past decade. While the company's 10-year median is 283.12 vs. the industry median of 90.98, PhotoCure ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhotoCure ASA's current Days Payable of 202.97 is 123.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PhotoCure ASA and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhotoCure ASA's current Days Payable is 202.97, which is 28% below median its own 10-year median of 283.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.33, compared to a current price of €5.23 — trading 17.4% below its estimated fair value. The current Days Payable is 202.97, which is 28% below median its 10-year median of 283.12 and 123.1% above the Drug Manufacturers industry median of 90.98. PhotoCure ASA's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current Days Payable is 202.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of €5.23 is trading 17.4% below its estimated GF Value™ of €6.33.
GuruFocus considers PhotoCure ASA to be Modestly Undervalued.
Key valuation signals for FRA:PHS:
Days Payable: 202.97 (28% below median its 10-year median of 283.12)
GF Value™: €6.33 vs. price of €5.23 (17.4% below fair value)
Industry Position: 123.1% above the Drug Manufacturers median (#150 of 923)
No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
73GF Score
Get the complete analysis for FRA:PHS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHS has been successfully added to your 
